Scancell, the developer of novel immunotherapies for the treatment of cancer, has developed a technique where DNA is injected into patients to create T-cells that recognise and destroy cancer cells.
While the global pandemic continues to affect our everyday lives, it is important to adapt quickly to a fast changing environment. Several of our portfolio companies have rapidly pivoted to play their part in the fight against COVID-19, and we would like to highlight their efforts below. Mologic A medical diagnostics firm Omega Diagnostics has CE-Marked … Continued
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, announces that it has initiated a research programme to develop a vaccine for COVID-19. The project will be led by Professor Lindy Durrant, Chief Scientific Officer and Professor of Cancer Immunotherapy at the University of Nottingham, in collaboration with scientists in the … Continued
Follows successful validation by Liverpool School of Tropical Medicine and St George’s, University of London With manufacturing support from Omega Diagnostics, the laboratory-based test aims to deliver up to 46,000 results per day Health services and key worker communities in the UK and Africa will be prioritised for access Bedfordshire, UK, 20 APRIL 2020: Mologic Ltd, a … Continued
Oxford BioTherapeutics (“OBT”) a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, announced that Boehringer Ingelheim (“BI”) has selected a second asset to advance into formal IND enabling studies. The asset discovery was enabled by OBT’s proprietary OGAP® target discovery platform. It is one of several assets that have … Continued
The Association of Investment Companies (AIC) has spoken to investment company and VCT managers about the prospects for a vaccine and how their portfolio companies are contributing to the fight against coronavirus. John Glencross, Chief Executive, told of three Calculus portfolio companies, Mologic, Genedrive and Yourgene. Read the full press release here Are any of … Continued
Calculus portfolio company Yourgene Health PLC has unveiled a contract manufacturing agreement with Novacyt SA for a COVID-19 diagnostic test. Under the deal, Yourgene will use its manufacturing facility in Manchester, UK, to ramp up production of Novacyt’s COVID-19 test, with the first batches to be shipped from the Manchester site in the next few … Continued
Genedrive, has pivoted part of its core resources towards development of two SARS-COV-2 tests, which can determine whether someone is infected with coronavirus. The first assay, already in development, is an instrument-agnostic molecular assay (the Genedrive® 96 SARS-COV-2 test) that can be performed on a variety of high throughput molecular testing platforms already installed in many … Continued
Calculus Capital is committed to providing the same level of service to our valued investors and advisers, and continuing to guide and support our portfolio companies, during this unprecedented time. Our EIS Funds and VCT remain open for investment with a number of new deals about to be made over the coming weeks and months. … Continued
With remote working becoming a new norm, the time is now for Media Asset Management (MAM) to power global video talent to collaborate and continue to create without constraint World leaders in MAM software, IPV, has announced the immediate launch of ‘CuratorNow‘, a private cloud, remote editing studio for professional video editors and producers to continue … Continued